Manual article review is required for this article
Manual article review is required for this article
Manual article review is required for this article
Manual article review is required for this article
Dyne Therapeutics is creating therapeutics for individuals with genetically-driven muscle mass disorders. Throughout the development of prospective therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy form one (DM1), Dyne sought the viewpoints of individuals living with these illnesses to inform its clinical trial style and to red